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Abstract: Mantle cell lymphoma is a relatively rare B-cell lymphoma with a specific 
genetic lesion and a typical immunophenotypic profile. The median age is 65 years. There 
is no curative treatment, except allogeneic stem cell transplantation for a selected group 
of patients. For the majority of patients, especially the elderly, the aim of therapy should 
therefore be a long progression-free survival. Age and comorbidity may hamper the use of 
the most active treatment regimen, such as high dose cytarabine and autologous stem cell 
transplantation. Therefore, it is a challenge to select the most appropriate therapy for an elderly 
patient. Studies specifically designed for elderly patients are rare. A recently performed large 
randomized study for elderly patients, however, has shown that R-CHOP (rituximab with 
cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by 
maintenance rituximab can result in a long progression-free survival. For patients too frail for 
R-CHOP chemotherapy, a treatment should be offered that benefits the patient in reducing the 
symptoms of the disease without causing too many side effects. Progression or relapse will 
occur in all patients sooner or later. Second-line treatment should again be carefully selected. 
Several options are mentioned. New drugs are being developed, and new combinations are 
investigated. Further improvement in the outcome of patients with mantle cell lymphoma is 
expected. Participation in well-designed clinical trials, also by elderly patients, is important 
to find the real benefit that can be achieved, and to get information on the tolerability of these 
treatments in this age group.
Keywords: treatment, chemotherapy, malignant lymphoma, mantle cell lymphoma, elderly, 
MCL
Introduction
Malignant lymphoma, or non-Hodgkin’s lymphoma, is not a single disease, but a 
name for a group of different disease entities that originate from mature lymphocytes. 
Histologic, immunologic, and genetic features are used to discriminate the 
different entities. In the World Health Organization classification of hematological 
malignancies, the lymphomas are described in the chapters on mature B- and T-cell 
neoplasms.1
Mantle cell lymphoma (MCL) is one of the well-recognized B-cell lymphomas. 
It has a specific genetic lesion, and a characteristic immunophenotype. It is relatively 
rare, comprising 5%–7% of the lymphomas.2 More than 50% of patients is 65 years 
or older. There is a striking male predominance, with 60%–70% of the patients being 
male. MCL has some typical clinical features. It used to have a poor prognosis, but in 
recent years the outcome of treatment has shown major improvements.3






The diagnosis of a malignant lymphoma cannot be made 
without an adequate biopsy, preferably from a lymph node. 
MCL typically shows a proliferation of monotonous small or 
medium sized lymphocytes with inconspicuous nucleoli. In a 
minority of cases, a blastoid variant is present. In these cases, 
the malignant cells are larger, have multiple nucleoli, and a 
high proliferation rate, and a diffuse large B-cell lymphoma 
might be mistakenly suspected. Immunohistochemically, 
MCL cells express the B-cell markers CD79b and CD20. 
Typical for MCL is the co-expression of the T-cell marker 
CD5. The co-expression of CD5 is also common in chronic 
lymphocytic leukemia (CLL). To make the distinction 
between MCL and CLL, CD23 is an important marker: in 
MCL, CD23 is usually not positive, whereas in CLL, there 
is co-expression of CD5 and CD23.1
The genetic lesion in MCL is a translocation between 
chromosome 11 and chromosome 14, t(11;14)(q13;q32). The 
proto-oncogene CCND1 on chromosome 11q13 is continu-
ously activated by the Ig heavy chain gene on 14q32. This 
results in the overexpression of cyclin D1 mRNA, resulting 
in continuous cell proliferation. The protein cyclin D1 can be 
easily demonstrated by immunohistochemistry, and is the hall-
mark of MCL. Only in rare cases, MCL is cyclin D1 negative. 
This might be suspected if other features, such as morphology 
and immunology are typical for classical MCL. In these cases, 
cyclin D2 or cyclin D3 can be overexpressed.4
Thus the typical immunohistochemical features are CD5 
positive, CD23 negative, and cyclin D1 positive. The prolif-
eration marker Ki-67 shows a variable expression.
Staging
When the diagnosis of a malignant lymphoma has been made, 
it is important to investigate the localizations of disease. The 
results will influence treatment, and are important for response 
assessment. Most patients with MCL present with advanced 
disease, with a generalized lymphadenopathy. Moreover, MCL 
tends to spread to extranodal localizations, ie, bone marrow, 
liver, skin, or gastrointestinal. The gastrointestinal localization 
can occasionally present as multiple intestinal polyposis. Only 
a minority of patients with gastrointestinal localization have 
symptoms.5 Massive splenomegaly is not uncommon. Bone 
marrow examination shows MCL infiltration in the majority 
of patients. In up to 25% of cases, the disease is leukemic, 
with MCL cells circulating in the peripheral blood. Therefore, 
a distinction with CLL should be made (see above). Flow 
cytometry of the peripheral blood will detect MCL cells in a 
much higher frequency than by morphology only.6
Later in the course of the disease, MCL infiltration can 
be observed in otherwise rarely affected localizations, such 
as the central nervous system.7–9
The staging procedure includes physical examination, 
blood count, lactate dehydrogenase, computed tomography 
scan of neck, thorax, abdomen, and pelvis, and a bone marrow 
aspiration and biopsy. Flow cytometry of the bone marrow 
is advised. An FDG-PET (fluorodeoxyglucose-enhanced 
positron emission tomography) scan is still considered 
investigational.10 The sensitivity of FDG-PET for extranodal 
localizations is low.11 A negative end-of-treatment scan has 
a high negative predictive value for relapse, but does not 
predict for better survival. False-positive PET scans are not 
uncommon.
Examination of cerebrospinal fluid, both morphologic and 
by flow cytometry, should be performed in the case of neuro-
logic complaints. If gastrointestinal symptoms are present, a 
gastroscopy or colonoscopy should be considered.
The results of the staging procedures are used for the 
classification in four staging groups, according to the Ann 
Arbor classification (Table 1).12 Systemic symptoms defined 
as fever without definitive cause, night sweats, or more than 
10% weight loss in less than 6 months are mentioned in the 
Ann Arbor classification as B-symptoms.
Prognosis
MCL has a gradually or rapidly progressive course. Real 
indolent cases, showing no progression for many years, 
are recognized, but rare. The typical clinical presentation 
of this indolent subgroup usually is a marked leukocytosis 
and splenomegaly, in the absence of lymphadenopathy.13 





Involvement of a single lymph node region or  





Involvement of two or more lymph node regions on the same 
side of the diaphragm or  
localized involvement of an extralymphatic site in combination 







Involvement of lymph node regions on both side of the diaphragm 
with infiltration of spleen or 
with localized involvement of an extralymphatic site or  
with infiltration of spleen and localized involvement of an 
extralymphatic site
IV Diffuse or disseminated infiltration of one or more extralymphatic 
organs or tissues, with or without lymphadenopathy
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Aside from this rare subgroup, most patients need therapy 
to reduce symptoms, or to prevent deteriorating disease. 
Patients with a blastoid variant of MCL are more likely to 
have a rapidly progressive course, and a poor response on 
chemotherapy.
In MCL, several clinical factors are recognized that influ-
ence the prognosis. The MIPI (MCL International Prognostic 
Index) score has been developed based upon clinical factors 
that are present at diagnosis. The clinical risk factors that 
negatively influence outcome are: higher age, performance 
status .1, higher lactate dehydrogenase, and higher leuco-
cyte count. With these variables, the score can be calculated 
that stratifies the patients into three groups. The median 
overall survival (OS) in the good prognosis group was not 
reached; in the intermediate group, 51 months; and in the 
poor prognosis group, 29 months. For clinical practice, a 
simplified MIPI is suggested.14
The proliferation rate of the cells is another prognostic 
factor.15,16 The pathologist can determine the proliferation 
rate with the Ki-67 antibody. In the MIPIb (combined 
biological index), the percentage of Ki-67-positive cells is 
incorporated.14
Therapy of newly diagnosed  
MCL, general principles
Treatment of patients with MCL used to result in a poor 
outcome, with a 5-year OS of 27%.2 However, the median 
OS has changed over the last decade, by introduction of 
new therapeutic options. Because of these new evolving 
therapeutic options, there is no standard treatment regimen 
for MCL, as new studies are continuously showing further 
improvements.
The first major improvement has been the introduc-
tion of the anti-CD20 monoclonal antibody rituximab, in 
combination with the standard CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone) regimen. The 
complete remission rate improved, and the progression-free 
survival (PFS) observed after R-CHOP (rituximab with 
CHOP) treatment was 18 months, although this did not 
seem to improve the OS.17,18 A meta-analysis of randomized 
controlled trials, including 260 MCL patients, indicated a sur-
vival benefit in patients treated with immunochemotherapy 
compared with chemotherapy only.19 The important role 
of rituximab has not only been observed in clinical trials 
and meta-analysis, but also in an observational population-
based study. The addition of rituximab in this study has 
resulted in an improvement of median survival from 27 to 
37 months.20
The introduction of high dose cytarabine (Ara-C) in the 
treatment of MCL has been another change resulting in a 
better outcome. Several regimens are used.21–24
Finally, consolidation with autologous transplantation 
was shown to prolong survival of MCL patients.25 The 
conditioning regimen before the autologous transplantation 
might be intensive chemotherapy, ie, BEAM (consisting of 
bis-chloroethylnitrosourea, etoposide, cytarabine, and mel-
phalan) or include total body irradiation.26,27
Only a minority of MCL patients have stage I disease. 
Patients with stage I disease have been excluded from 
most clinical trials, assuming that limited chemotherapy 
followed by local radiotherapy as in stage I diffuse large 
B-cell lymphoma is very effective. However, this has not 
been formally studied in a randomized trial. A retrospective 
study in 26 MCL patients with stage I or II disease showed 
the importance of radiotherapy in limited disease.28 Patients 
receiving radiotherapy as part of the induction therapy had 
a significantly better 5-year PFS: 73% versus 13% without 
radiotherapy. There was a trend for better PFS in stage I 
compared to stage II disease (5-year PFS, 73% versus 20%). 
Although the numbers were small, the authors concluded that 
limited cycles of multi-agent chemotherapy with radiotherapy 
might be the treatment of choice in this group of patients. 
A recent retrospective study confirmed the better outcome 
of stage I compared with stage II patients, with combined 
modality treatment. The 5-year PFS was 44%; the 5-year 
OS, 62%.29
Treatment of elderly patients
For many elderly patients, an intensive treatment with 
high dose cytarabine and transplantation is too toxic. 
There is no clear definition of elderly in this respect. 
Arbitrarily, clinical trials often use a cutoff of 65 years 
or older. However, even some patients less than 65 might 
be considered as elderly, in the case of cardiac disease 
or other comorbidity. With a median age of 65 years at 
diagnosis of MCL, half of the patients are not eligible for 
the “standard” therapy with autologous transplantation. 
However, even with a less intensive treatment the outcome 
of the fit elderly patient has improved by incorporating 
rituximab and maintenance therapy.
Studies investigating minimal residual disease have 
shown that those patients achieving a molecular complete 
remission after therapy have a low risk of early progression, 
and in general have a long event-free survival. It is therefore 
important to try to obtain a complete remission, also for 
elderly patients.30





The backbone of therapy is R-CHOP. This regimen is 
repeated every 3 weeks, up to eight courses. The result is gen-
erally a reduction of lymphadenopathy and other symptoms. 
Overall responses (complete and partial remissions com-
bined) of approximately 85% can be obtained. A complete 
remission (CR), no signs of disease left on computed tomog-
raphy scan and other restaging procedures, is achieved in 
30%–40% of patients.18,31 Relapse or progression is common 
after 2–3 years.18
The European MCL Network designed a study that 
aimed to improve the results of induction therapy, and 
to prolong the duration of remission. In this randomized, 
multicenter study, the standard R-CHOP, eight cycles, was 
compared with rituximab, the purine analog fludarabine, 
and cyclophosphamide (R-FC), every 4 weeks, a total of six 
cycles. The responding patients were randomized between 
maintenance therapy with interferon-alpha or rituximab. 
This maintenance treatment was planned to continue until 
progression.31 In almost 7 years, 560 patients from eight 
countries were randomized. The median age was 70 years. 
The results were unexpected. The new induction regimen 
R-FC did not improve the outcome; in both treatment arms 
the response rate (partial response and complete response) 
was not statistically different: after R-CHOP 86%, after 
R-FC 78%. The CR rate was 34% and 40% respectively, 
also not statistically different. The OS in the R-CHOP-
treated patients was better than in the R-FC-treated 
patients, the survival rate after 4 years being 62% versus 
47%. The toxicity of R-FC was more severe, especially 
hematologic toxicity, and infections were observed more 
frequently.
The outcome of the maintenance treatment was very 
much in favor of rituximab. After 4 years, 58% of the patients 
had not shown progression or relapse, compared with 29% 
of the patients that started interferon maintenance. This 
resulted in a 4-year OS in the patients treated with R-CHOP 
and rituximab maintenance of almost 85%. Eight cycles of 
R-CHOP followed by rituximab maintenance therefore now 
is considered the standard treatment for elderly patients with 
MCL, until a new study will hopefully show further improved 
outcome data.
An alternative alkylating agent is bendamustine. This 
agent has been used for the treatment of indolent lymphomas 
and MCL in Germany for more than 20 years, but was only 
approved in Europe and US a few years ago. In a recently 
randomized study in patients with indolent lymphoma or 
MCL, R-CHOP has been compared with R-bendamustine.32 
The study was designed as a noninferiority trial. The toxicity 
of R-bendamustine was lower, except for skin rash. Erythema 
or allergic reactions of the skin were observed in 31% of the 
patients, compared with 15% after R-CHOP. Ninety-four 
patients in this study (18%), with a median age of 70 years, 
were diagnosed with a MCL. The median PFS of the MCL 
patients was 35 months with R-bendamustine, compared 
with 22 months after R-CHOP. No difference in OS has been 
observed, however. A second study, not yet published, for 
indolent lymphomas including MCL, has been initiated in 
the USA. In this study, R-bendamustine is being compared 
with R-CHOP or R-CVP (rituximab with cyclophosphamide, 
vincristine, and prednisone).
Treatment of the frail elderly 
patient
For the frail elderly patient, therapy should aim to reduce 
symptoms and maintain quality of life. Usually, the very 
elderly patient, or the patient with severe comorbidity, cannot 
be treated with R-CHOP. A less intensive regimen should 
be selected to reduce symptoms. In some patients, R-CVP 
might be feasible: doxorubicin is responsible for many of 
the side effects of R-CHOP, ie, nausea and vomiting and 
neutropenia. There is no risk to further reduction of cardiac 
function without the administration of doxorubicin.
An alternative for the frail elderly is oral chlorambucil 
that might be combined with rituximab. This is a well-
tolerated regimen in most patients.33
The results of monotherapy rituximab are not very 
impressive. An overall response rate of 27% has been 
observed, with an event-free survival of 6 months, which 
is less than can be obtained in follicular lymphoma. Longer 
treatment did not significantly improve the outcome.34
Finally, in the case of localized symptomatic lymphade-
nopathy, local control can be obtained by radiotherapy.35
Therapy of relapsed or progressive 
elderly MCL patients
Although the results of upfront treatment have improved, 
finally patients will show relapse or progressive disease. 
There is no standard therapy for relapse or progression. Sev-
eral options are mentioned as follows (overview in Table 2). 
Most of the studies with relapsed/refractory patients are not 
specifically designed for elderly patients, but most of them 
have included elderly patients as well, as is reflected in the 
median age.
Rituximab/bendamustine is an active regimen for MCL, 
and can be used in the relapsed setting.36 Retreatment with 
bendamustine is possible, although no details are known 
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about its effectiveness in MCL.37 Combination therapy with 
mitoxantrone may be an option.38
Fludarabine/cyclophosphamide (FC) is also active in 
relapsed MCL.39 The combination rituximab, fludarabine, 
cyclophosphamide, and mitoxantrone (R-FCM) can result 
in a response rate of 58%–79%.40,41 However, R-FCM is not 
suitable for patients who have received CHOP because of 
the cumulative cardiac anthracycline toxicity. Maintenance 
rituximab does not significantly improve the response dura-
tion but increases the number of patients with remissions 
beyond 2 years.41
The major side effect of fludarabine-containing regi-
mens is hematologic toxicity. In the upfront setting, R-FC 
was inferior compared with R-CHOP, mainly caused by 
increased toxicity.31 However, fludarabine is an effective 
drug in the treatment of MCL, and it might be considered in 
the relapse setting. It is important to select the fitter patients 
for this treatment.
Most elderly patients have not received high dose cytara-
bine in first-line treatment. There are some data that show 
a reduced dose cytarabine is also effective. This might be 
considered in the relapse setting. In a Phase II study in elderly 
patients, the combination rituximab, bendamustine, and 
cytarabine (R-BAC) has been explored. Twenty patients had 
been previously treated. The R-BAC regimen was effective, 
but had a high rate of myelosuppression. A new study with 
a lower dose of cytarabine has been started.42
Monotherapy with the purine nucleoside analog cladrib-
ine has shown some activity in relapsed MCL, with relatively 
low toxicity.43
In the US, the proteasome inhibitor bortezomib has 
been approved for the treatment of relapsed or progressive 
MCL. Activation of the nuclear factor kappa B (NF-κB) is 
an important result of the activated proliferation pathway 
in MCL. Bortezomib has been shown to inhibit NF-κB 
activation. Monotherapy with bortezomib can result in 
a response rate of 30%–45%, but a median PFS of only 
6 months.44,45 The major side effect of bortezomib is neu-
ropathy, either a sensory neuropathy or neuropathic pain. 
With the recently introduced use of subcutaneous instead 
of intravenous administration, the risk of neuropathy has 
decreased.46 Combination of bortezomib with cytarabine has 
also been explored, and seems feasible with a dose adjust-
ment for elderly patients.47
In Europe, temsirolimus, an mTOR (mammalian target 
of rapamycin) kinase inhibitor, is approved for relapsed 
MCL. In the PI3K/AKT pathway, which plays a major role 
in the proliferation of MCL, mTOR is one of the regulatory 
proteins. So it seemed attractive to investigate this drug in 
relapsed MCL. In relapsed/refractory MCL, single-agent 
temsirolimus achieves a response in 40% of patients, with 
only 3% complete remissions, however. The median duration 
of response is only 6 months.48,49 In a randomized Phase III 
study, temsirolimus has been compared to single-agent 
Table 2 Overview of optional therapy choices for elderly patients with relapsed or refractory mantle cell lymphoma
Publication Regimen N Responses Median response duration Median age (years)
Rummel et al36 BR (bendamustine, rituximab) 16 ORR 75% 
CR 50%
PFS 18 months 66
weide et al38 BMR (bendamustine, mitoxantrone,  
rituximab)
18 ORR 77% 
CR 33%
PFS 21 months 
OS at 2 years 60%
66
Thomas et al39 FC (fludarabine, cyclophosphamide) 16 ORR 75% 
CR 56%
TTF 11 months 65
Forstpointner et al40 R-FCM (rituximab, fludarabine,  
cyclophosphamide, mitoxantrone)
24 ORR 58% 
CR 29%
PFS 8 months 
OS at 2 years 65%
65
visco et al42 R-BAC (rituximab, bendamustine,  
cytarabine)
20 ORR 80% 
CR 70%
PFS at 2 years 70% 70
Inwards et al43 Cladribine 24 ORR 46% 
CR 21%
PFS 5.4 months 
OS at 2 years 36%
68
Fisher et al44 Bortezomib 155 ORR 33% 
CR 8%
DR 9.2 months 
OS not reached
65
Hess et al50 Temsirolimus 108 ORR 22% 
CR 2%
PFS 4.8 months 
OS 12.8 months
68
Habermann et al52 Lenalidomide 15 ORR 53% 
CR 20%
PFS 5.6 months 
DR 13.7 months
66
weigert et al47 R-HAD + B (rituximab, cytarabine,  
dexamethasone, bortezomib)
8 ORR 50% 
CR 25%
PFS 5.5 months 
OS 15 months
65
Abbreviations: ORR, overall response rate; CR, complete response rate; PFS, progression-free survival; TTF, time to treatment failure; DR, duration of response; 
OS, overall survival.





physician’s choice therapy. Again, in a heavily pretreated 
group of patients, with a median of three previous lines of 
therapy (range 2–7), the PFS with temsirolimus monotherapy 
was only 5 months. The major toxicities of temsirolimus are 
thrombocytopenia, diarrhea, and asthenia.50
Lenalidomide, an immunomodulatory drug that is active 
in several B-cell malignancies, has been studied in relapsed 
MCL. The reported response rates are 42%–55%, with a 
PFS of 6 months.51,52 To date, no randomized studies with 
lenalidomide have been performed in MCL, but these results 
are promising.
In a selective group of younger patients, an allogeneic 
transplantation may be considered after successful re-
induction therapy. An allogeneic transplantation is the only 
curative option, but the treatment-related mortality is consid-
erable, up to 30%. Acute and chronic graft versus host disease 
is common, and has a major impact on quality of life.53
In elderly patients an allogeneic transplantation will rarely 
be the choice of therapy.
In a palliative setting, radiotherapy is an attractive option 
to treat symptoms resulting from enlarged lymph nodes. 
MCL is radiosensitive, so radiotherapy is useful to achieve 
local control.35
New developments
In young patients, both R-DHAP (rituximab with dexam-
ethasone, cytarabine, and cisplatin) or single-agent high dose 
cytarabine have been used successfully to improve outcome. 
Based on these results, it seems attractive to explore whether 
an induction regimen with cytarabine is also feasible in 
elderly patients. Improvement of the response rate, and espe-
cially the CR-rate, could lead more patients to maintenance 
therapy, and further improve outcome.
Although the R-DHAP regimen is considered too toxic 
for most elderly patients, a modification might result in 
acceptable toxicity and still be effective. Some experience 
in relapsed patients is promising. The European MCL Net-
work will initiate a new randomized study to investigate a 
cytarabine-based treatment in elderly patients.
Several other drugs have shown promising results in 
MCL, and are being studied.
Lenalidomide is an immunomodulatory drug, which is 
very active and widely used in the treatment of multiple 
myeloma, both in induction and maintenance therapy. 
It has shown promising results in MCL, as mentioned 
before. It is an oral agent, with limited side effects, and 
therefore very attractive for use in the maintenance setting. 
The European MCL Network will investigate the role 
of lenalidomide as a maintenance treatment in its next 
elderly study.
New small molecule drugs are being developed with 
novel mechanisms of action.
The PI3K/AKT/mTOR pathway is subject to the develop-
ment of new active drugs. A constitutive activation of this 
pathway results in survival of the tumor cells. PI3K delta 
is inhibited by idelalisib, GS1101 (formerly CAL-101). This 
drug has shown clinical activity in relapsed MCL. More 
clinical studies have been performed in CLL. There is a good 
clinical activity, but up to 5% of the patients develop severe 
liver enzyme disturbances.
Some other agents that inhibit signal transduction compo-
nents of the B-cell receptor pathway had disappointing results 
in early clinical trials. Fostamatinib, a SYK inhibitor, was 
not very active in a Phase I/II study.54 Enzastaurin, a protein 
kinase C beta (PKC-β) inhibitor, induced no response in a 
Phase II study with 60 patients. The median time to progres-
sion was 2 months.55
The B-cell receptor signaling pathway is activated in 
many B-cell malignancies. Bruton’s tyrosine kinase (BTK) 
is essential in this pathway. A new BTK-inhibitor, ibrutinib, 
shows very promising results in early trials in MCL. This oral 
agent is non-myelosuppressive and seems a breakthrough in 
the treatment of CLL and MCL. Phase III studies are initiated 
and currently accruing patients.56–58
Conclusion
MCL is a malignant lymphoma that has shown major 
improvement in outcome, both in younger and elderly 
patients. However, relapses occur sooner or later. Several 
promising agents are being developed. It is of importance that 
patients, also those of high age, are encouraged to participate 
in clinical trials, to investigate the role of new treatment 
approaches and new drugs.
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